Key facts
- This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Mar 2022, 15:49.
Stephane Bancel - 01 Mar 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MRNA
- Reported as of
- 01 Mar 2022
- Net transaction value
- -$1,344,960
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 15:49:03 UTC
- Prior SEC filing
- 25 Feb 2022
- Next SEC filing
- 04 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 25 Feb 2022.
- Current net transaction value: -$1,344,960.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Gift
- Transaction value
- Shares
- -150,000
- Change %
- -2.6%
- Price
- Shares after
- 5,534,535
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $1,344,960
- Shares
- -9,000
- Change %
- -0.16%
- Price
- $149.44
- Shares after
- 5,525,535
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
MRNA
transaction
Common Stock
Gift
- Transaction value
- Shares
- -4,000
- Change %
- -0.07%
- Price
- Shares after
- 5,521,535
- Date
- 02 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F3
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,050,372
- Date
- 01 Mar 2022
- Ownership
- See Footnote
- Footnotes
- F4
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,004,880
- Date
- 01 Mar 2022
- Ownership
- See Footnote
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +146,364
- Change %
- Price
- $0.000000
- Shares after
- 146,364
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 146,364
- Exercise price
- $149.52
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The reported disposition represents a bona fide charitable gift made by the reporting person.
Footnote F2
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
Footnote F3
The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
Footnote F4
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F5
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F6
25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.